Learn Before
Relation
Discussion
- The vaccine was determined to be safe and well tolerated as a two dose immunization in both age groups, all participants produced a humoral immune response.
- Minimal adverse effects were reported, and all that were reported were mild or moderate, and the lab results came back normal.
- In the older age group (60+ years of age), the safety and tolerability was evaluated. The rate of seroconversion was slower than in the younger age group (Day 28 for the 4 and 8 μg dose and Day 42 for the 2 μg dose), and the overall production of neutralizing antibodies was lower as well.
- The analysis of the antibody titers after the second dose suggests the use of a booster immunization.
- No notable changes in lymphocyte subsets or cytokine production, which is similar to other studies.
- The study is limited by the short duration, and the absence of specific study of children and adolescents. The study of children will proceed in the ongoing phase 1 trials after the adult groups are finalized.
0
1
Updated 2020-10-26
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences